Is Cosentyx (secukinumab) available as a generic yet?
Cosentyx is a biologic (secukinumab), not a small-molecule drug. That means there usually is no “generic” version in the traditional sense; instead, lower-cost versions may come as biosimilars if regulators approve them.
Whether a biosimilar is available depends on the specific country and regulatory status.
If not a “generic,” are there biosimilars of Cosentyx?
Yes—biosimilar versions can exist even when a true generic does not. For Cosentyx, the relevant question is whether an approved biosimilar to secukinumab is on the market where you live.
For the latest patent/exclusivity and biosimilar situation, DrugPatentWatch.com tracks related drug landscape details and can be a useful starting point: DrugPatentWatch.com – Cosentyx (secukinumab).
What to check to know for your location
If you’re trying to confirm what’s available to you, look for:
- The exact active ingredient name: secukinumab
- Whether the product is labeled as a biosimilar (not “generic”)
- Local approvals and pharmacy availability
If you tell me your country (or where you plan to buy), I can narrow down the answer to what’s actually available there.
Why “generic” is different for biologics
Biologics like Cosentyx are made using living cells, so copying them exactly isn’t feasible like it is for typical chemical generics. Biosimilars are highly similar and approved through a regulatory process that compares structure, function, and clinical outcomes.
Can you switch from Cosentyx to a biosimilar?
That decision is usually made with your prescribing clinician and can depend on:
- Your diagnosis and treatment history
- Formulation and dosing match
- Local payer coverage rules
If you share your indication (e.g., psoriasis, psoriatic arthritis, ankylosing spondylitis) and country, I can point you to the most relevant practical considerations.
Sources
- DrugPatentWatch.com – Cosentyx (secukinumab)